ArticleEClinicalMedicine2025

Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial.

Xutao Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.